The Governance Truth-Telling Deficit: How Does Honesty Get From the Frontline to the Boardroom Before It's Too Late?
By David Nicholson
Failures in digital health transformation programmes gone awry were not surprises springing up out of nowhere. They were foreseen, raised, minuted and crucially, overridden by momentum. So why weren’t they seen and more importantly acted on?
In the cases that should worry boards most, the warning signs were visible: clinical concerns were raised, workflow impacts were known, infrastructure and data dependencies were unresolved, and governance forums existed but did not force the evidence to matter. The practical challenge for any organisation overseeing a major digital health programme is not simply deciding when to go live. It is knowing what evidence would require a pause, a reset, or a different route to success and building the structures that make sure that evidence actually reaches the people making the decision.
So the board question should not only be, ‘when will the system go live?’ They should also ask, ‘what evidence would tell us it should not go live yet and who is empowered to show us that evidence?'
If the answer is silence, the problem is already larger than the risk register suggests as honesty must be survivable for those who know the system is not ready, they need to be able to say so out loud.
The Anatomy of a Foreseen Failure
Many reviews of failed or distressed programmes tell a consistent story. The greatest risks are rarely only technical, they sit in the joins between clinical workflow, operational practice, data quality, integration, infrastructure, supplier accountability, workforce readiness and executive decision-making. When these things are treated as peripheral, and not integral, to programmes early warning signs are missed.
Governance structures may exist on paper, but clinical and operational risks do not always translate into decisive action. This is often due to budget control, supplier pressure and milestone reporting sitting in one space, while the clinical organisation that will live with the system sits in another. Platforms are then deployed into high-pressure workflows they were never properly tested against: system freezes, locked records, slow access to patient information, failed integrations, medication chart risks, workarounds, duplicate documentation and confidence in the programme is lost.
When go-live proceeds despite unresolved clinical and opearational risk, rollbacks follow like night after day, and too often when clinicians and teams raise serious concerns before rollout those concerns can be treated as friction rather than evidence. We must ask, when will that happen for the last time?
The true cost of remediation
The cost of a lack of readiness compounds quickly. A programme that begins as a £180 million business case could bloat to £259 million, then £320 million, much of the growth driven by remediation, delay and reversal. And the financial escalation is only one part of the damage. Delay, unrealised benefits, lost clinical confidence, low team morale and public value erosion are often the larger costs. When data governance, interoperability, infrastructure readiness and workflow ownership are weak at the start, the organisation pays for that weakness later, usually under greater pressure and with fewer good options.
None of this is really about the tech. It is about whether the organisation has built the capability to be an intelligent buyer and governor of transformation. Clinical voices need real checked authority, workflows need to be understood before they are digitised, data needs to be treated as an asset, not an afterthought. Infrastructure and integration need to be assured before they become load-bearing and supplier promises need to be tested against objective requirements and time.
Above all, governance needs to maintain the golden thread from strategy through procurement, implementation, benefits and safe operation.
Why Momentum Often Beats Evidence
It is easy to see how large programmes develop their own gravity. Contracts are signed, milestones are public, careers and political capital are attached to the date. Every month of delay has a reputational cost; the cost of proceeding unready is invisible until go-live makes it spectacularly visible and by that time, those responsible are often gone. In that environment, 'are we ready?' becomes a question nobody junior can afford to answer truthfully, unless the organisation has deliberately built the structures that make truth-telling survivable.
The failures we’ve seen started long before the crisis. It is worth being contextual about why this keeps happening, because it is not incompetence, although some of these issues can lead to gross negligence.
When we talk about readiness at Tektology it is not a phase on a plan to be compressed when the timeline slips. It is the standing capacity to answer board-level questions with evidence: mapped clinical workflows that show how care is actually delivered; structured feedback channels that turn frontline concerns into programme risks; a realistic view of digital literacy, change capacity and workforce adoption; infrastructure, integration and data governance assessed before they carry clinical load; benefits and business case assumptions traced through delivery; and explicit decision gates where clinical safety, operational risk and readiness gaps are scored before implementation decisions are made.
A data platform without ownership, standards and trust produces more dashboards, not better decisions. An EMR deployed onto unready workflows and an unengaged workforce does not transform care; it industrialises dysfunction and hands the consequences to public-facing clinicians. Technology, people, process and data have to move together, the weakest link there sets the ceiling for the whole investment.
The same logic applies to intelligent new hospitals, another area we work in. The hard operating challenge sits in the messy middle between patient state, building state, operational action and accountable decision-making. If a bed is unavailable, a discharge is delayed, an asset is missing, a room is not ready, a patient is deteriorating, or an environmental condition may affect care, the value is not in knowing more. The value is in what the organisation does differently because of that knowledge: who sees it, who owns the action, what is automated, what is escalated, what is measured, and how the system learns.
The Cheapest Insurance a Health System Will Buy
Boards sometimes hesitate to fund substantial readiness work before a system has even been selected. The inquiry arithmetic answers that hesitation: the cost of disciplined readiness will be paid in weeks or months and is a fraction of programme budget. Set that against the cost of remediation, delay, rollback and broken clinical trust, which will be paid in years and nine figures.
Readiness is not a delay to transformation. It is the difference between a go-live that lands successfully and a rollback. It is the cheapest insurance a health system will ever buy.
This is where Tektology does some of its best work. On the client side, before and throughout implementation, we are the party in the room whose job it is to build the structural conditions where hard truths are survivable to say, and evidence is difficult to override.
That role sits behind everything else we do. It shapes how we assess readiness across people, process, technology and data. It shapes how we run workflow reviews so that frontline concerns become programme risks rather than user complaints. It shapes the architecture guardrails, data and integration principles, benefits logic, and safety gates we put in front of the decisions that matter. And it shapes the standing we bring to the board room, so that when someone in the programme needs to say 'not yet', there is a mechanism, and a voice, that makes that decision survivable rather than career-limiting.
Ask It Now
The challenge should be laid down where it belongs: at the start, not the end. Boards that ask 'when do we go live?' without also asking 'what evidence would stop us going live and who are the right people empowered to tell us?' are governing by hope.
And in major digital health transformation, hope is not a strategy.
David Nicholson is Global CEO of Tektology, where he works with governments and health systems on large-scale transformation, particularly at the intersection of capital, digital and operating model redesign. Alongside his role at Tektology, he is Chair of the Independent Digital Group and a member of the Independent Technical Review Panel for the UK's New Hospital Programme.